Pyxis Oncology PYXS
NASDAQ PYXS
$1.77 -0.07 (-3.53%)
As of: Oct 21, 2026 · 3:16 PM EDT

Pyxis Oncology (PYXS) Current Deferred Revenue (2023)

Updated

Pyxis Oncology's Current Deferred Revenue came in at $7.66 million for Q4 2023, up 6.4% from the prior quarter.

Analysis

Pyxis Oncology (PYXS) Current Deferred Revenue (2023) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,137.48 Bn 1,106.07 Bn 19.71 Bn
2 Johnson & Johnson 618.81 Bn 537.34 Bn 17.26 Bn
3 AbbVie 502.02 Bn 475.14 Bn 12.70 Bn
4 Merck 368.25 Bn 322.63 Bn 12.21 Bn
5 Novartis Ag 297.87 Bn 261.86 Bn 11.24 Bn
6 Astrazeneca 260.90 Bn 234.58 Bn 12.86 Bn
7 Amgen 236.67 Bn 192.07 Bn 7.24 Bn
8 Gilead Sciences 191.16 Bn 165.36 Bn 6.22 Bn
9 Pfizer 169.69 Bn 116.34 Bn 10.94 Bn
10 Pyxis Oncology 113.59 Mn -151.47 Mn -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2023 7.66 Mn
Sep 30, 2023 7.20 Mn
API Access

Pyxis Oncology Current Deferred Revenue API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=current-deferred-revenue&ticker=PYXS&period=max&api_key=YOUR_API_KEY